Andrea A Hayes-Jordan1, Brian A Coakley2, Holly L Green3, LianChun Xiao4, Keith F Fournier2, Cynthia E Herzog5, Joseph A Ludwig6, Mary F McAleer7, Peter M Anderson8, Winston W Huh5. 1. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ahjordan@mdanderson.org. 2. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Pediatric Surgery, Children's Hospital of Los Angeles, Los Angeles, CA, USA. 4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 7. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. 8. Department of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland, OH, USA.
Abstract
BACKGROUND: Desmoplastic small round cell tumor (DSRCT) is a rare sarcoma that primarily affects adolescents and young adults. Patients can present with many peritoneal implants. We conducted a phase 2 clinical trial utilizing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) with cisplatin for DSRCT and pediatric-type abdominal sarcomas. PATIENTS AND METHODS: A prospective cohort study was performed on 20 patients, who underwent CRS-HIPEC procedures, with cisplatin from 2012 to 2013. All patients were enrolled in the phase 2 clinical trial. Patients with extraabdominal disease and in whom complete cytoreduction (CCR0-1) could not be achieved were excluded. All outcomes were recorded. RESULTS: Fourteen patients had DSRCT, while five patients had other sarcomas. One patient had repeat HIPEC. Patients with DSRCT had significantly longer median overall survival after surgery than patients with other tumors (44.3 vs. 12.5 months, p = 0.0013). The 3-year overall survival from time of diagnosis for DSRCT patients was 79 %. Estimated median recurrence-free survival (RFS) was 14.0 months. However, RFS for patients with DSRCT was significantly longer than for non-DSRCT patients (14.9 vs. 4.5 months, p = 0.0012). Among DSRCT patients, those without hepatic or portal metastases had longer median RFS than those with tumors at these sites (37.9 vs. 14.3 months, p = 0.02). In 100 % of patients without hepatic or portal metastasis, there was no peritoneal disease recurrence after CRS-HIPEC. CONCLUSIONS: Complete CRS-HIPEC with cisplatin is effective in select DSRCT patients. DSRCT patients with hepatic or portal metastasis have poorer outcomes.
BACKGROUND:Desmoplastic small round cell tumor (DSRCT) is a rare sarcoma that primarily affects adolescents and young adults. Patients can present with many peritoneal implants. We conducted a phase 2 clinical trial utilizing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) with cisplatin for DSRCT and pediatric-type abdominal sarcomas. PATIENTS AND METHODS: A prospective cohort study was performed on 20 patients, who underwent CRS-HIPEC procedures, with cisplatin from 2012 to 2013. All patients were enrolled in the phase 2 clinical trial. Patients with extraabdominal disease and in whom complete cytoreduction (CCR0-1) could not be achieved were excluded. All outcomes were recorded. RESULTS: Fourteen patients had DSRCT, while five patients had other sarcomas. One patient had repeat HIPEC. Patients with DSRCT had significantly longer median overall survival after surgery than patients with other tumors (44.3 vs. 12.5 months, p = 0.0013). The 3-year overall survival from time of diagnosis for DSRCT patients was 79 %. Estimated median recurrence-free survival (RFS) was 14.0 months. However, RFS for patients with DSRCT was significantly longer than for non-DSRCT patients (14.9 vs. 4.5 months, p = 0.0012). Among DSRCT patients, those without hepatic or portal metastases had longer median RFS than those with tumors at these sites (37.9 vs. 14.3 months, p = 0.02). In 100 % of patients without hepatic or portal metastasis, there was no peritoneal disease recurrence after CRS-HIPEC. CONCLUSIONS: Complete CRS-HIPEC with cisplatin is effective in select DSRCT patients. DSRCT patients with hepatic or portal metastasis have poorer outcomes.
Authors: W L Gerald; M Ladanyi; E de Alava; M Cuatrecasas; B H Kushner; M P LaQuaglia; J Rosai Journal: J Clin Oncol Date: 1998-09 Impact factor: 44.544
Authors: Joel M Baumgartner; Steven A Ahrendt; James F Pingpank; Matthew P Holtzman; Lekshmi Ramalingam; Heather L Jones; Amer H Zureikat; Herbert J Zeh; David L Bartlett; Haroon A Choudry Journal: J Surg Oncol Date: 2013-02-05 Impact factor: 3.454
Authors: Eleanor Marshall Osborne; Tina Marie Briere; Andrea Hayes-Jordan; Lawrence B Levy; Winston W Huh; Anita Mahajan; Peter Anderson; Mary Frances McAleer Journal: Radiother Oncol Date: 2015-10-30 Impact factor: 6.280
Authors: Paul H Sugarbaker; Robert Alderman; Gary Edwards; Christina Ellen Marquardt; Vadim Gushchin; Jesus Esquivel; David Chang Journal: Ann Surg Oncol Date: 2006-03-10 Impact factor: 5.344
Authors: Zachary E Stiles; Andrew J Murphy; Doralina L Anghelescu; Christina-Lin Brown; Andrew M Davidoff; Paxton V Dickson; Evan S Glazer; Michael W Bishop; Wayne L Furman; Alberto S Pappo; John T Lucas; Jeremiah L Deneve Journal: Ann Surg Oncol Date: 2019-04-08 Impact factor: 5.344
Authors: Kevin X Liu; Natalie B Collins; Katie A Greenzang; Elissa Furutani; Kevin Campbell; Andrew Groves; Elizabeth A Mullen; Suzanne Shusterman; Jennifer Spidle; Karen J Marcus; Brent R Weil; Christopher B Weldon; A Lindsay Frazier; Katherine A Janeway; Allison F O'Neill; Jennifer W Mack; Steven G DuBois; David S Shulman Journal: Pediatr Blood Cancer Date: 2020-07-19 Impact factor: 3.167
Authors: Florencia Cidre-Aranaz; Sarah Watson; James F Amatruda; Takuro Nakamura; Olivier Delattre; Enrique de Alava; Uta Dirksen; Thomas G P Grünewald Journal: Nat Rev Dis Primers Date: 2022-10-06 Impact factor: 65.038
Authors: Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle Journal: Ecancermedicalscience Date: 2022-02-17
Authors: Fiorela N Hernandez Tejada; Alejandro Zamudio; Mario L Marques-Piubelli; Branko Cuglievan; Douglas Harrison Journal: Curr Oncol Rep Date: 2020-11-16 Impact factor: 5.075
Authors: Emily K Slotkin; Anita S Bowman; Ahmet Zehir; Marc Ladanyi; Neerav Shukla; Max F Levine; Filemon Dela Cruz; Diego F Coutinho; Glorymar I Sanchez; Nestor Rosales; Shakeel Modak; William D Tap; Mrinal M Gounder; Katherine A Thornton; Nancy Bouvier; Daoqi You; Gunes Gundem; Justin T Gerstle; Todd E Heaton; Michael P LaQuaglia; Leonard H Wexler; Paul A Meyers; Andrew L Kung; Elli Papaemmanuil Journal: Mol Cancer Res Date: 2021-03-22 Impact factor: 6.333
Authors: Shakeel Modak; Pat Zanzonico; Milan Grkovski; Emily K Slotkin; Jorge A Carrasquillo; Serge K Lyashchenko; Jason S Lewis; Irene Y Cheung; Todd Heaton; Michael P LaQuaglia; Nai-Kong V Cheung; Neeta Pandit-Taskar Journal: J Clin Oncol Date: 2020-10-29 Impact factor: 44.544